Biotechnology News 9 December 2025

Viridian Therapeutics, Inc. (VRDN) Stock Surges on Dec. 15, 2025: Latest News, Analyst Forecasts, and 2026 Catalysts

Viridian Therapeutics, Inc. stock (Nasdaq: VRDN) is back in the spotlight on December 15, 2025, as shares push to fresh highs amid a mix of sector news, new Wall Street coverage, and a shifting competitive landscape in thyroid eye disease

15 December 2025

Analyst Forecasts·Biotechnology·Financial Trends·Investment News·Stock Market

Immunovant (IMVT) Stock News and Forecast for Dec. 14, 2025: $550M Financing Closes, Roivant Buys $350M, Analysts Update Targets

Immunovant, Inc. (NASDAQ: IMVT) stock is closing out the week in focus after the company completed a major equity raise designed to bolster funding for its autoimmune pipeline—while its controlling shareholder, Roivant Sciences, stepped in as the largest buyer. As

14 December 2025

Analyst Ratings·Biotechnology·Financial Analysis·Investment Strategies·Stock Market News

Amicus Therapeutics (FOLD) Stock News, Forecasts and Analyst Outlook on Dec. 14, 2025: What’s Driving the Rally?

Amicus Therapeutics (NASDAQ: FOLD) is near a 52-week high after strong results and bullish analyst coverage. Here’s the latest news, forecasts, catalysts, and key risks as of Dec. 14, 2025. As of Sunday, December 14, 2025 (with U.S. markets closed),

14 December 2025

Biotechnology·Financial News·Investment Analysis·Stock Forecasts·Stock Market

CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL Limited shares closed Friday at A$183.93, ending a volatile week only slightly lower overall after a sharp rebound into the weekend. Investors are weighing two very different storylines at once: encouraging long-term clinical data for CSL’s hemophilia B gene

14 December 2025

Biotechnology·Investment Insights·Market Updates·Pharmaceutical Industry·Stock Analysis

Vertex Pharmaceuticals (VRTX) Stock: This Week’s News, Analyst Forecasts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Updated: Dec. 12, 2025 (U.S. market close) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) finished Friday at $452.04, extending a late-week rebound after a choppy start to the week. The stock’s intraday range on Friday stretched from $442.94 to $455.99 on volume

13 December 2025

Analyst Forecasts·Biotechnology·Financial News·Investment Analysis·Stock Market

Geron Stock (NASDAQ: GERN) News Today: Restructuring, Analyst Ratings, and 2026 Catalysts (Dec. 12, 2025)

Geron Corporation (NASDAQ: GERN) stock is back in focus on December 12, 2025, as investors digest a sweeping restructuring tied to the company’s commercial push for RYTELO (imetelstat) and its longer-term clinical ambitions. The headlines have been loud—one-third of the

12 December 2025

Biotechnology·Company News·Financial Analysis·Investing·Stock Market

Applied Therapeutics (APLT) Stock News Today: Cycle Deal Details, CVR Upside, and Analyst Outlook (Dec. 12, 2025)

NEW YORK — December 12, 2025 — Applied Therapeutics, Inc. (NASDAQ: APLT) is in the spotlight after announcing a definitive agreement to be acquired by Cycle Group Holdings Limited (“Cycle”), a rare-disease-focused company that operates as Cycle Pharmaceuticals. The headline

12 December 2025

Biotechnology·Financial Updates·Investment Analysis·Pharmaceutical News·Stock Market

10x Genomics (TXG) Stock: Citi Downgrade, AI Partnerships and 2026 Forecast After December 11 Sell-Off

10x Genomics, Inc. (NASDAQ: TXG) — a leading player in single-cell and spatial biology — is back in the spotlight after a sharp share-price drop on 11 December 2025. A high-profile analyst downgrade from Citigroup hit the stock the same

11 December 2025

Artificial Intelligence·Biotechnology·Financial Forecasts·Investment Analysis·Stock Market

Wave Life Sciences (WVE) Stock on December 11, 2025: Obesity Breakthrough, 180% Rally, $350M Offering and Fresh Analyst Targets

Updated: December 11, 2025 – all figures and ratings as of publication; this article is for information only and is not investment advice. Key takeaways WVE stock today: from under‑the‑radar biotech to market spotlight Wave Life Sciences Ltd. (NASDAQ: WVE),

11 December 2025

Analyst Ratings·Biotechnology·Pharmaceutical Industry·Stock Market

Arrowhead Pharmaceuticals (ARWR) Stock Near 52‑Week High After FDA Approval and New Alzheimer’s Trial: Latest News & Forecasts as of December 11, 2025

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has quietly turned into one of 2025’s wildest biotech comeback stories. After years as a perpetually “promising” RNA interference (RNAi) platform, the company now has: The stock price has responded in full drama mode. As of

11 December 2025

Biotechnology·FDA Approvals·Investment Analysis·Pharmaceutical Industry·Stock News

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

NEW YORK – December 11, 2025 – Shares of Immunovant, Inc. (NASDAQ: IMVT) were sharply in focus on Thursday after the clinical‑stage immunology company announced a $550 million common stock financing designed to fund development and a potential commercial launch

11 December 2025

Biotechnology·Healthcare News·Investments·Pharmaceuticals·Stock Market

Arcellx (ACLX) Stock Surges on Anito-cel Breakthrough Data as Analysts Boost Price Targets – December 9, 2025

Published: December 9, 2025 Arcellx, Inc. (NASDAQ: ACLX) has jumped back onto Wall Street’s radar after releasing highly positive Phase 2 data for its multiple myeloma cell therapy anitocabtagene autoleucel (“anito-cel”) at the American Society of Hematology (ASH) 2025 meeting.

9 December 2025

Analyst Ratings·Biotechnology·Financial Updates·Investment News·Stock Market

Biotechnology News 9 December 2025 - 15 December 2025